Pharmaceutical firm Aurobindo Pharma today said it has received approval from the Medicines Control Council (MCC) to manufacture and market nine products in South Africa.

<tr><td><p class='TableClas'></p><P class='TableClas'><DIV CLASS=rightDiv><script language="JavaScript">
		google_ad_client = 'businessstandard';
		//google_ad_client = 'ca-businessstandard_js';
		google_ad_width = 200;
		google_ad_height = 200;
		google_ad_format = "200x200_as";
		google_ad_type = "text";
		google_ad_channel = "";
		//google_color_border = "FFFFFF";
		google_color_border = "F7F7F7";
		//google_color_bg = "FFFFFF";
		google_color_bg = "ffffff";
		//google_color_link = "639ACE";
		google_color_link = "0253B7";
		google_color_text = "000000";
		google_color_url = "D63431";
		//google_skip = adsenseSkip;
		</script> 
		<script type="text/javascript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js">
		</script> </DIV><p class='TableClas'>These products are estimated to have a generic market size of ZAR 165 million in the local market, the company said in a filing to the Bombay Stock Exchange (BSE). Aurobindo has a total of 31 marketing authorisations approved by the MCC, the company added.
</p><p class='TableClas'>Out of the nine products, Zinoxime and Yomax are anti-infective, while Auro-Lisinopril Co, Auro-Amlodipine and Lisinozide are cardio-vascular system drugs. The other products that received the approval include Auro-Finasteride, Zolid, Lazivir and Profina. </P></p><p class='TableClas'></p></table>


Gets nod to market nine products in South Africa

More From This Section

Posco land acquisition resumes amid protests

Diageo to buy half of Mallya's South Africa beer biz

Average money spent for new players dips

'IndiGo did not comply with AAC guidelines'

Explore News